Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination (Q33185958)

23 July 2017

title

Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination (English)

1 reference

23 July 2017

Angela Kather

1

1 reference

23 July 2017

Alfonso Ferrara

2

1 reference

23 July 2017

Marion Nonn

3

1 reference

23 July 2017

Manuela Schinz

4

1 reference

23 July 2017

John Nieland

5

1 reference

23 July 2017

Achim Schneider

6

1 reference

23 July 2017

Matthias Dürst

7

1 reference

23 July 2017

Andreas M Kaufmann

8

1 reference

23 July 2017

language of work or name

English

0 references

publication date

1 April 2003

1 reference

International Journal of Cancer

23 July 2017

published in

1 reference

23 July 2017

volume

104

1 reference

23 July 2017

issue

3

1 reference

23 July 2017

page(s)

345-353

1 reference

Estimates of the worldwide incidence of 25 major cancers in 1990.

23 July 2017

cites work

1 reference

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

21 January 2018

1 reference

Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer.

21 January 2018

1 reference

Potential immunogenicity of oncogene and tumor suppressor gene products

21 January 2018

1 reference

Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen

21 January 2018

1 reference

Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.

21 January 2018

1 reference

Immunological events in regressing genital warts

21 January 2018

1 reference

Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens

21 January 2018

1 reference

A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.

21 January 2018

1 reference

A pilot study of perilymphatic leukocyte cytokine mixture (IRX-2) as neoadjuvant treatment for early stage cervical carcinoma

21 January 2018

1 reference

Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine

21 January 2018

1 reference

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

21 January 2018

1 reference

Synthetic peptides induce a cytotoxic response against human papillomavirus type-18.

21 January 2018

1 reference

CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer

21 January 2018

1 reference

Improved tools for biological sequence comparison

21 January 2018

1 reference

An improved flow cytometric assay for the determination of cytotoxic T lymphocyte activity

21 January 2018

1 reference

A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity

21 January 2018

1 reference

The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays

21 January 2018

1 reference

Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study

21 January 2018

1 reference

A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study

21 January 2018

1 reference

Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study

21 January 2018

1 reference

Adenocarcinoma of the cervix associated with human papillomavirus

21 January 2018

1 reference

Expression of a single-chain HLA class I molecule in a human cell line: presentation of exogenous peptide and processed antigen to cytotoxic T lymphocytes

21 January 2018

1 reference

B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes

21 January 2018

1 reference

Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors

21 January 2018

1 reference

Multiple mechanisms underlie HLA dysregulation in cervical cancer

21 January 2018

1 reference

Heteroclitic immunization induces tumor immunity

21 January 2018

1 reference

Nomenclature for factors of the HLA system, 1998.

21 January 2018

1 reference

Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV e6‐e7 anti‐sense RNA

21 January 2018

1 reference

Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial

21 January 2018

1 reference

Expression of CD80 enhances immunogenicity of cervical carcinoma cells in vitro

21 January 2018

1 reference

Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability

21 January 2018

1 reference

Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions

21 January 2018

1 reference

Stage IB and IIA cervical cancer with negative lymph nodes: the role of adjuvant radiotherapy after radical hysterectomy

21 January 2018

1 reference

Small-cell neuroendocrine carcinoma of the cervix. A human papillomavirus type 18-associated cancer

21 January 2018

1 reference

Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.10940

1 reference

23 July 2017

1 reference